Orphan drug prices on non-orphan meds? Gilead, this means you, PBM says

Anyone following the hepatitis C drug market knows that Express Scripts CMO Steve Miller has a strong point of view. Now, he's turned to the Gilead ($GILD) follow-up to its blockbuster Sovaldi, a combo med dubbed Harvoni that aims to take the place of older cocktails, with a list price of $94,500 for 12 weeks. Per pill, that works out to $1,125. Miller's argument? That's orphan drug-level pricing. And with 2.4 million patients to treat in the U.S., Harvoni is not an orphan drug. Report